At a glance
ClinicalIndex Comparison RecordN/ACompleted· 29 enrolled
Drug / intervention
fluocinolone acetonide (Retisert Implant, Bausch and Lomb)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
In Brief
A clinical study evaluating fluocinolone acetonide (Retisert Implant, Bausch and Lomb) for Central Retinal Vein Occlusion. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a fluocinolone sustained drug delivery implant is effective in the treatment of central retinal vein occlusion that has caused persistent macular edema and decreased visual acuity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Retinal Vein Occlusion
CountriesUnited States
CollaboratorsBausch & Lomb Incorporated
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2002
Primary CompletionMay 2009
First PostedAug 2009
TodayJul 2026
First PostedAug 6, 2009
Enrollment StartOct 1, 2002
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 16.9 years ago
Interventions
fluocinolone acetonide (Retisert Implant, Bausch and Lomb)device
sustained release device consisting of 0.59 mg of fluocinolone acetonide